(R)-3-Amino-1-Butanol CAS 61477-40-5 Puritas >99.0% (GC) Dolutegravir Intermedia Factory

Description:

Chemical Name: (R)-3-Amino-1-Butanol

Synonyma: (R) Aminobutan-1-ol

CAS: 61477-40-5

Puritas: >99.0% (GC)

Aspectus: hyalina ad lux Yellow Liquid

Medium Dolutegravir (CAS: 1051375-16-6)

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (R)-3-Amino-1-Butanol (CAS: 61477-40-5) with high quality, commercial production. It's an intermediate of Dolutegravir (CAS: 1051375-16-6). We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available, strong after-sale service. Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	(R) -3-Amino-1-Butanol
Synonyma	(R) -3-Aminobutan-1-ol;(3R)-3-Amino-1-Butanol
CAS Number	61477-40-5
CATTUS Number	RF-CC317
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C4H11NO
M. Pondus	89.14
Gravitas Imprimis (20/20)	0.95
Index refractivus	1.45
Imprimis rotationis [α]20/D	-12.0° ~ -10.0° (C=1, EtOH)
Brand	Ruifu Chemical

Specifications:

Aspectus	Hyalina lux Yellow Liquid	Lux Yellow Liquid
Lepidium sativum IR	Conformat spectrum de Standard	Conforms
Lepidium sativum per GC*	Conformat cum retentione tempus de Latin	Conforms
Puritas per GC (A%)	>99.0%	99.8%
Substantiae cognatae	Ulla immunitas: <0.5%	0.09%
Substantiae cognatae	Totalis immunditias: <1.0%	0.28%
S-Isomer (per HPLC A%)	<0.10%	0.02%
Water Content by KF	<0.50%	0.10%
GC (w/w%)	>99.0%	99.3%

Sarcina & Repono:

sarcina: Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam mos

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

(R) -3-Amino-1-Butanol (CAS: 61477-40-5) adhiberi potest ut medium in praeparatione compositorum HIV integrarum actionis inhibitoriae habentis.(R)-3-Amino-1-Butanol medium est Dolutegravir (CAS: 1051375-16-6).Dolutegravir (Tivicay) novum genus medicamenti anti-ADIS fuit, quod a gigante GlaxoSmithKline (GSK) pharmaceutico Britannico coniunctim elaboratum est cum Societate Pharmaceutica Shionogi Iaponica (Shionogi).Mense Augusto 2013, US FDA approbavit dolutegravir (etiam ad S/GSK1349572) tractationem contagionis HIV-1 in adultis et pueris saeculis XII annorum et maior in compositione cum aliis medicamentis antiretroviralibus.